| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.33 | 5e-26 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.31 | 3e-19 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.3 | 3e-19 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.39 | 2e-18 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.24 | 9e-11 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.19 | 3e-08 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.24 | 6e-08 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-07 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-06 |